Herombopag

Phase 2Small molecule

JJiangsu HengRui Medicine Co., Ltd.

Herombopag is one of 34 small molecule programs targeting Thrombocytopenia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaRecruiting

ThrombocytopeniaPhase 2

Recruiting

Competition

Competitive Landscape

40 competitors in Thrombocytopenia

#DrugCompanyPhaseTrials

Doptelet

AAkarx

Approved

18 2

Medrol

Pfizer

Approved

2 3

Fragmin

Pfizer

Approved

1 4

Innohep

Jazz Pharmaceuticals

Approved

1 5

Lovenox

Sanofi

Approved

1 6

Promacta

GSK

Phase 3

13 7

Angiomax

BBaxter Healthcare Corporation

Approved

2 8

Actemra

CCelltrion

Approved

1 9

Rayos

RRoxane Laboratories

Approved

—10

Rapamune

PPrism Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Thrombocytopenia

NCT07198672

Clinical

Trials by Indication[1]

Thrombocytopenia4 trials

Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag

Not yet recruiting·ZZhenzhen Liu·N/A·NCT07198672·45 enrolled

Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06745219·30 enrolled

A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

Unknown status·SSuxiaLuo··NCT05130424·498 enrolled

Show 1 more trial

Herombopag for Chemotherapy-induced Thrombocytopenia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05236582·50 enrolled

Immune Thrombocytopenia2 trials

Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT05685420·117 enrolled

Herombopag + rhTPO in Severe Immune Thrombocytopenia

Unknown status·YYin Jie·Phase 3·NCT05328804·90 enrolled

Severe Aplastic Anemia1 trial

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05660785·54 enrolled

Chronic Liver Disease1 trial

The Efficacy and Safety of Herombopag in Treating Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery - A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT06507436·127 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Herombopag. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Herombopag compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Herombopag. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

Herombopag

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Thrombocytopenia4 trials

Immune Thrombocytopenia2 trials

Severe Aplastic Anemia1 trial

Chronic Liver Disease1 trial

References

Drug Info

Quick Facts

Related News